Home/ Stocks/ UNCY

Unicycive Therapeutics, Inc. Common Stock

UNCY XNAS

$6.39 -0.07 (-1.03%) ▼ 15-min delayed

Open

$6.75

High

$6.75

Low

$6.31

Volume

615.3K

Market Cap

$145.50M

About Unicycive Therapeutics, Inc. Common Stock

Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 22 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q3 2025	$0	$-6,011,000	$-0.33
Q2 2025	$0	$-6,447,000	$-0.52
Q1 2025	$0	$570.0K	$0.03
FY 2024	$0	$-36,729,000	$-0.56

Related Market News

No specific coverage for UNCY yet. Check out our latest market news or earnings calendar.

Get UNCY Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Unicycive Therapeutics, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.